Austar Lifesciences Limited provided unaudited group earnings guidance for the six months ended 30 June 2019. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2019 and the information currently available to the Board, the Group is expected to record a turnaround to profit attributable to the owners of the Company for the six months ended 30 June 2019 as compared with a loss attributable to the owners of the Company of approximately RMB 3.7 million for the six months ended 30 June 2018. The Board attributes the expected turnaround from loss to profit principally to an increase in revenue mainly attributable to: (i) the high level of backlog as at 31 December 2018 and the order-in-take of the Group, resulting in higher amount of revenue being recognised during the six months ended 30 June 2019; and (ii) an improved project execution management.